Session Description

Secondary immunodeficiencies (SID) with hypogammaglobulinemia may be induced by therapeutic agents used to treat autoimmune manifestations and hematological malignancies. Given the highly variable presentations of primary immunodeficiencies (PID), antibody deficiencies initially attributed as secondary cause of treatment of hematological malignancies or autoimmune conditions may actually underlie a PID. The objective of this symposium is to explore SID and PID crossovers and discuss the challenges for accurate diagnosis and suitable treatment strategies.

Session Description

Secondary antibody deficiency (SAD) is common in patients with haematological malignancies, such as chronic lymphocytic leukaemia (CLL), multiple myeloma (MM) or after advanced therapies like B-cell targeting monoclonal antibodies or CAR T-cell therapy. During the session, our experts will discuss the latest advances on how to reduce infection burdens in these high-risk patients, for whom these infections remain a major cause of morbidity and mortality.